Cost Effectiveness of Different Treatment Strategies in the Treatment of Patients with Moderate to Severe Rheumatoid Arthritis in China

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Wu, Bin ^a   Wilson, Alisa ^b   Wang, Fang fang ^a   Wang, Su li ^a   Wallace, Daniel J ^b   Weisman, Michael H ^b   Lu, Liang jing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD COMPLEX; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CHINA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; OUTPATIENT; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; STRATEGIC PLANNING; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHINA; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOGLOBULIN G; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84867644293     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047373     Document Type: Article

References (39)

1. Dai SM, Han XH, Zhao DB, Shi YQ, Liu Y, et al. (2003) Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China: a COPCORD study. The Journal of rheumatology 30: 2245-2251.
2. Zeng QY, Chen R, Darmawan J, Xiao ZY, Chen SB, et al. (2008) Rheumatic diseases in China. Arthritis research & therapy 10: R17.
3. Schoels M, Wong J, Scott DL, Zink A, Richards P, et al. (2010) Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Annals of the rheumatic diseases 69: 995-1003.
4. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the rheumatic diseases 69: 964-975.
5. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P, (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370: 1861-1874.
6. Klareskog L, Catrina AI, Paget S, (2009) Rheumatoid arthritis. Lancet 373: 659-672.
7. Gibbons LJ, Hyrich KL, (2009) Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy 23: 111-124.
8. Wang X-r, Su Y, An Y, Zhou Y-s, Zhang X-y, et al. (2012) Survey of tumor necrosis factor inhibitors application in patients with rheumatoid arthritis in China. Beijing da xue xue bao Yi xue ban = Journal of Peking University Health sciences 44: 182-187.
9. van der Velde G, Pham B, Machado M, Ieraci L, Witteman W, et al. (2011) Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis care & research 63: 65-78.
10. Bansback NJ, Brennan A, Ghatnekar O, (2005) Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Annals of the rheumatic diseases 64: 995-1002.
11. Hu D, Bao C, Chen S, Gu J, Li Z, et al. (2009) A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China. Rheumatology international 29: 297-303.
12. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, et al. (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New England Journal of Medicine 340: 253-259.
13. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932-1939.
14. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis and rheumatism 48: 35-45.
15. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis and rheumatism 50: 1400-1411.
16. Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, et al. (2010) Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. The Journal of rheumatology 37: 917-927.
17. Brennan A, Bansback N, Reynolds A, Conway P, (2004) Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 43: 62-72.
18. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, et al. (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis and rheumatism 62: 22-32.
19. Wilson DL, (1994) The analysis of survival (mortality) data: fitting Gompertz, Weibull, and logistic functions. Mechanisms of ageing and development 74: 15-33.
20. Life tables for WHO Member States. http://www.who.int/healthinfo/statistics/mortality_life_tables/en/. Accessed 2012 September 18.
21. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A (2004) The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis - Introduction. Health technology assessment 8: 1-+.
22. Boggs R, Sengupta N, Ashraf T, (2002) Estimating health utility from a physical function assessment in rheumatoid arthritis (RA) patients treated with Adalimumab (D2E7). Value in Health 5: 452-453.
23. Kielhorn A, Tony H, Jost F, Aultman R, (2006) Rituximab in rheumatoid arthritis: Translating ACR responses into benefit for the patients. Annals of the rheumatic diseases 65: 324-325.
24. Kielhorn A, Porter D, Diamantopoulos A, Lewis G, (2008) UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Current medical research and opinion 24: 2639-2650.
25. Hallinen TA, Soini EJ, Eklund K, Puolakka K, (2010) Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology 49: 767-777.
26. Kobelt G, Eberhardt K, Jonsson L, Jonsson B, (1999) Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis and rheumatism 42: 347-356.
27. Yelin E, Wanke LA, (1999) An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis and rheumatism 42: 1209-1218.
28. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B, (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research 7: 518-528.
29. Murray CJ, Evans DB, Acharya A, Baltussen RM, (2000) Development of WHO guidelines on generalized cost-effectiveness analysis. Health economics 9: 235-251.
30. Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM, (2008) Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clinical therapeutics 30: 1939-1955.
31. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, et al. (2009) Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane database of systematic reviews: CD007848.
32. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, et al. (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health technology assessment 10: iii-iv, xi-xiii, 1-229.
33. van den Hout WB, (2009) Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA. Nature clinical practice Rheumatology 5: 78-79.
34. Kay J, (2011) Biosimilars: a regulatory perspective from America. Arthritis research & therapy 13: 112.
35. Gu N, Yi S, Kim TE, Kim J, Shin SG, et al. (2011) Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers. Clinical therapeutics 33: 2029-2037.
36. Rosenblum H, Amital H, (2011) Anti-TNF therapy: safety aspects of taking the risk. Autoimmunity reviews 10: 563-568.
37. Isaacs JD, (2009) Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists. Expert opinion on biological therapy 9: 1463-1475.
38. Merkesdal S, Kirchhoff T, Wolka D, Ladinek G, Kielhorn A, et al. (2010) Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure. The European journal of health economics: HEPAC: health economics in prevention and care 11: 95-104.
39. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, et al. (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis & Rheumatism-Arthritis Care & Research 59: 762-784.